Test Price
1,800 AED✅ Home Collection Available
NPM1+ CEBPA Mutation Analysis in UAE | 1800 AED | 2026 DHA Guidelines
تحليل طفرات NPM1+ CEBPA في الإمارات | 1800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي
- ●Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing, ensuring reliable mutation detection for clinical decision-making.
- ●Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain transport, with VIP Mobile Phlebotomy available 8 AM – 11 PM daily.
- ●Clinical Guidance: Complimentary telephonic post-test clinical correlation session with a specialist to interpret your results in the context of your health history.
- ●Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 before sample collection.
Clinical Overview
The NPM1+ CEBPA Mutation Analysis is a targeted DNA sequencing test that identifies somatic mutations in the NPM1 and CEBPA genes, essential for the diagnostic workup, prognostic stratification, and minimal residual disease monitoring of acute myeloid leukemia (AML). This dual-gene panel provides actionable results within 7–8 days using gold-standard Sanger Sequencing, directly informing therapeutic choices and transplant decisions.
| Feature | Our Test (AMLexpert™ UAE) | Closest Alternative (Standard Lab) |
|---|---|---|
| Methodology | Sanger Sequencing (Gold Standard, full coding region) | qPCR/Fragment Analysis (limited mutation coverage) |
| Sensitivity | Down to 5% mutant allele frequency | Often 10–20%, missing low-level clones |
| TAT | 7–8 days | 10–14 days |
| Sample Stability | Cold-chain logistics, immediate transport | Uncontrolled collection, delayed processing |
Physician Insight & Safety Protocol
"As a molecular haematopathologist, I emphasize that a negative NPM1 or CEBPA result does not exclude AML; these mutations must always be correlated with bone marrow morphology, cytogenetics, and clinical presentation. This test is a powerful tool for risk adaptation, but treatment decisions—especially for favourable-risk NPM1-mutated AML—should only be made after comprehensive multidisciplinary review."
— Dr. PRABHAKAR REDDY, DHA License No. 61713011, Consultant Haematopathologist
⚠ Medication Warning
Do not discontinue prescribed medication (e.g., hydroxyurea, lenalidomide, or targeted therapy) without consulting your treating physician. This test is for mutation profiling only and does not replace therapeutic monitoring.
🚨 Exclusion Criteria & Emergency Red Flags
- Active uncontrolled infection or fever > 38.5°C – postpone collection until stabilised.
- Patients on anticoagulants (except aspirin) require physician clearance for bone marrow aspiration.
- Seek immediate emergency care if you experience severe bruising, persistent bleeding at the site, or sudden shortness of breath after sample collection.
- This test is not intended for paediatric patients without DHA-approved parental consent (CDS Law 2026 – Minors).
Patient FAQ & Clinical Guidance
1. What is the clinical utility of NPM1+ CEBPA mutation testing?
This test detects mutations in the NPM1 and CEBPA genes to guide prognosis and treatment in acute myeloid leukemia. The results help haematologists determine whether you belong to a favourable, intermediate, or adverse risk group, directly impacting chemotherapy intensity and stem cell transplant timing.
ما الفائدة السريرية من اختبار طفرات NPM1+ CEBPA؟
يكتشف هذا الاختبار الطفرات في جيني NPM1 وCEBPA لتوجيه التشخيص والعلاج في ابيضاض الدم النقوي الحاد. تساعد النتائج أطباء أمراض الدم في تحديد مجموعة الخطورة الخاصة بك، مما يؤثر مباشرة على شدة العلاج الكيميائي وتوقيت زراعة الخلايا الجذعية.
2. How should I prepare for the sample collection, and what specimens are accepted?
You must provide a valid doctor’s prescription; no special fasting is required but immediate transport is mandatory. The test uses bone marrow aspirate or peripheral blood collected in EDTA tubes and must be processed within 24 hours under cold-chain conditions to preserve DNA integrity.
كيف أستعد لجمع العينة، وما العينات المقبولة؟
يجب تقديم وصفة طبية سارية؛ لا حاجة للصيام ولكن النقل الفوري إلزامي. يستخدم الاختبار نخاع العظم أو الدم المحيطي في أنابيب EDTA ويجب معالجته خلال 24 ساعة مع سلسلة تبريد للحفاظ على الحمض النووي.
3. Are there any legal or insurance considerations specific to UAE patients?
This requires a DHA-licensed physician’s prescription, except for surgery, pregnancy, or travel-abroad cases where different regulations apply. We comply with Federal Decree-Law No. 41 of 2024 and UAE PDPL; all genetic data is encrypted and processed solely within the UAE. Insurance pre-approval can be verified via WhatsApp before the visit.
هل هناك اعتبارات قانونية أو تأمينية خاصة بالمرضى في الإمارات؟
يتطلب الاختبار وصفة طبيب مرخص من هيئة الصحة بدبي، باستثناء حالات الجراحة أو الحمل أو السفر للخارج. نلتزم بالمرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية؛ جميع البيانات الجينية مشفرة وتُعالج حصراً داخل الدولة. يمكن التحقق من الموافقة المسبقة للتأمين عبر واتساب قبل الزيارة.
Regulatory Compliance: Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minors Consent), UAE Personal Data Protection Law (PDPL).
Facility License: DHA/MOHAP No. 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139
Support Hours: Home collection 8 AM – 11 PM daily. WhatsApp: +971 54 548 8731
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians